Hydroxyurea

Administration

• Type: Antineoplastic
• Dosage Forms:
• Routes of Administration: oral
• Common Trade Names:

Adult Dosing

• Cytoreduction in leukostasis and hyperleukocytosis/hyperviscosity syndrome
  • 50 to 100 mg/kg/day
• Sickle cell disease
  • 15-35 mg/kg/day
• CML, squamous cell head and neck cancer
  • 15mg/kg/day initially

Pediatric Dosing

• Off label for sickle cell, 10-35mg/kg/day

Special Populations

Pregnancy Rating

• D

Lactation risk

• Infant risk cannot be ruledout

Renal Dosing

• Reduce dose if CrCl <60. Administer after dialysis on HD days

Hepatic Dosing

• Adult:
• Pediatric:

Contraindications

• Allergy to class/drug

Adverse Reactions

Serious

• Skin ulceration, skin cancer, gangrene
• Genetic mutations w/longterm use
• Parvovirus infection

Common

• Myelosupression, neutropenia, thrombocytopenia, decreased reticulocyte count

Pharmacology

• Half-life: 2-4.5 hours
• Metabolism: Hepatic 60%
• Excretion: Renal(40%)

Mechanism of Action

• Inhibits DNA synthesis by acting as a ribonucleotide reductase inhibitor